Globally, there are more than 650,000 newly diagnosed cases of bladder cancer annually, with up to approximately 80% of these ...

The regulatory landscape for ANKTIVA saw critical developments regarding bladder cancer. ImmunityBio reported on January 20th that it held a Type B End-of-Phase meeting with the U.S. Food and Drug ...

With $202.3M in cash and an expanded $125M debt facility, ENGN is financially equipped to advance pivotal Cohort 1 and pursue ...

IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.

Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer$25 million advanced at close of the ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

Investing.com -- ImmunityBio Inc (NASDAQ:IBRX) stock surged 19.8% in premarket trading Tuesday after the company reported ...

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License ...

ImmunityBio Inc. (NASDAQ:IBRX) shares climbed nearly 20% in premarket trading on Tuesday after the company said it held positive discussions with the U.S. Food and Drug Administration regarding its ...

ImmunityBio shares jumped in premarket trading after the FDA outlined next steps for expanding ANKTIVA’s bladder cancer label ...